LogicBio Therapeutics, Inc

(NASDAQ:LOGC)

Latest On LogicBio Therapeutics, Inc (LOGC):

Date/Time Type Description Signal Details
2022-11-16 14:25 ESTNewsAstraZeneca's Alexion completes acquisition of genomic medicine company LogicBioN/A
2022-11-14 11:21 ESTNewsLogicBio GAAP EPS of -$0.18 beats by $0.02, revenue of $2.72M beats by $0.72MN/A
2022-10-03 13:25 ESTNewsLogicBio jumps 648% on buyout deal with AstraZeneca unit AlexionN/A
2022-08-15 18:03 ESTNewsLogicBio GAAP EPS of -$0.15, revenue of $3.2MN/A
2022-05-24 22:23 ESTNewsLogicBio Therapeutics (LOGC) Investor Presentation - SlideshowN/A
2022-05-16 14:46 ESTNewsLogicBio GAAP EPS of -$0.20, revenue of $2.81MN/A
2022-05-09 12:48 ESTNewsLogicBio surges as FDA lifts clinical hold on lead assetN/A
2022-03-05 01:32 ESTNewsLogicBio GAAP EPS of -$1.24 beats by $0.08, revenue of $5.41M beats by $0.56MN/A
2022-02-04 06:43 ESTNewsLogicBio downgraded at William Blair citing lack of clarity on catalysts after clinical holdN/A
2022-02-02 21:14 ESTNewsLogicBio falls on FDA clinical hold on gene therapy program for metabolic diseaseN/A
2021-11-22 05:25 ESTNewsWarning: LOGC is at high risk of performing badlyN/A
2021-08-09 10:42 ESTNewsLogicBio EPS misses by $0.14, misses on revenueN/A
2021-07-21 14:47 ESTNewsLogicBio trades higher as gene editing stocks rallyN/A
2021-04-27 20:08 ESTNewsLogicBio announces agreements with CANbridge Pharma and Daiichi SankyoN/A
2021-03-17 13:05 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 03:33 ESTNewsLogicBio EPS misses by $0.03, beats on revenueN/A
2021-03-16 21:18 ESTEarnings EstimateAn EPS average of -$1.44 is estimated for the 2022 year.Sell
2021-03-16 21:18 ESTEarnings EstimateAn EPS average of -$0.28 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-05 15:54 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.33 to $20.25.Neutral
2021-01-07 13:46 ESTNewsLogicBio extends collaboration with Children's Medical Research InstituteN/A
2021-01-06 16:04 ESTFinancialsCompany financials have been released.Neutral
2020-12-22 22:33 ESTNewsLogicBio Therapeutics names new CFON/A
2020-11-26 20:42 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 13:08 ESTNewsLooking In On LogicBioN/A
2020-11-12 12:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 12:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 04:21 ESTAnalyst RatingThe Analyst Target Price has decreased from $22 to $21.33.Neutral
2020-11-10 04:21 ESTEarnings EstimateAn EPS average of -$0.41 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-09 13:15 ESTNewsLogicBio reports Q3 resultsN/A
2020-11-07 16:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-05 08:43 ESTNewsLogicBio's LB-001 Fast Track'd for methylmalonic acidemia; shares +10%N/A
2020-11-05 08:43 ESTNewsLogicBio's LB-001 fast track'd in U.S. for an inherited metabolic disorderN/A
2020-11-04 05:37 ESTNewsLogicBio Therapeutics announces executive leadership changesN/A
2020-10-05 17:57 ESTInsider TradeErez Chimovits has indirectly acquired of 296,296 shares.Buy
2020-10-05 17:57 ESTInsider TradeErez Chimovits has indirectly acquired of 639,212 shares.Buy
2020-10-05 17:57 ESTInsider TradeErez Chimovits has indirectly acquired of 545,974 shares.Buy
2020-10-05 17:57 ESTInsider TradeORBIMED ADVISORS LLC has indirectly acquired of 296,296 shares.Buy
2020-10-05 17:57 ESTInsider TradeORBIMED ADVISORS LLC has indirectly acquired of 639,212 shares.Buy
2020-10-05 17:57 ESTInsider TradeORBIMED ADVISORS LLC has indirectly acquired of 545,974 shares.Buy
2020-10-05 17:15 ESTInsider TradeBioscience plc Arix has indirectly disposed of 273,584 shares.Sell
2020-10-05 17:15 ESTInsider TradeBioscience plc Arix has indirectly disposed of 174,219 shares.Sell
2020-10-05 17:15 ESTInsider TradeBioscience plc Arix has indirectly disposed of 38,514 shares.Sell
2020-10-01 17:12 ESTNewsLogicBio readies equity offeringN/A
2020-10-01 17:10 ESTNewsLogicBio Therapeutics -30% on pricing of equity offeringN/A
2020-09-26 13:17 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 05:24 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:21 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 05:12 ESTFinancialsCompany financials have been released.Neutral
2020-08-11 21:15 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.Buy
2020-08-11 05:05 ESTFinancialsCompany financials have been released.Neutral

About LogicBio Therapeutics, Inc (LOGC):

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. It has a partnership with Children's Medical Research Institute to develop new viral vectors; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop new genome editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company was founded in 2014 and is headquartered in Lexington, Massachusetts.

LOGC Quotes by TradingView

See Advanced Chart

General

  • Name LogicBio Therapeutics, Inc
  • Symbol LOGC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2018-10-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.logicbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 61.91
  • Price/Book (Most Recent Quarter) 4.4
  • Enterprise Value Revenue 62.53
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.16
  • Next Year EPS Estimate -$1.12
  • Next Quarter EPS Estimate -$0.35
  • Operating Margin -912%
  • Return on Assets -29%
  • Return on Equity -63%
  • Revenue 3.45 million
  • Earnings Per Share -$1.55
  • Revenue Per Share $0.14
  • Gross Profit 3.45 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 254.61 million
  • EBITDA -30350000
  • PE Ratio -0.64
  • Analyst Target Price $20.25
  • Book Value Per Share $1.93
View More

Share Statistics

  • Shares Outstanding 31.79 million
  • Shares Float 17.29 million
  • % Held by Insiders 1369%
  • % Held by Institutions 53%
  • Shares Short 827300
  • Shares Short Prior Month 677650
  • Short Ratio 6.35
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.31
  • 52 Week High $10
  • 52 Week Low $4.02
  • 50 Day Moving Average 8.36
  • 200 Day Moving Average 7.32
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

LogicBio Therapeutics, Inc (LOGC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

LogicBio Therapeutics, Inc (LOGC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.22-$0.3231.25%
2020-09-302020-11-09$N/A-$0.34-$0.4117.58%
2020-06-302020-08-10$N/A-$0.35-$0.4827.08%
2020-03-312020-05-11$1.02 million-$0.41-$0.4814.23%
2019-12-312020-03-16$N/A-$0.51-$0.49-5.15%
2019-09-302019-11-12$N/A-$0.48-$0.47-3.23%
2019-06-302019-08-13$N/A-$0.45-$0.40-12.5%
2019-03-312019-05-14$N/A-$0.34-$0.29-18.26%
2018-12-312018-12-31$N/A-$0.41-$0.39-5.13%
2018-09-302018-12-03$N/A-$4.03-$3.87-4.27%

LogicBio Therapeutics, Inc (LOGC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

LogicBio Therapeutics, Inc (LOGC) Chart:

LogicBio Therapeutics, Inc (LOGC) News:

Below you will find a list of latest news for LogicBio Therapeutics, Inc (LOGC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

LogicBio Therapeutics, Inc (LOGC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-1710CALL0 00TRUE00
2025-04-172.50CALL0 0153.98TRUE00
2025-04-1740CALL0 00TRUE00
2025-04-1751.15CALL0 10TRUE00
2025-04-1760.7CALL0 308685.04FALSE00
2025-04-177.50CALL0 00FALSE00
2025-04-1790CALL0 00FALSE00
2025-04-17100.29CALL0 100FALSE00
2025-04-1710PUT0 00FALSE00
2025-04-172.50PUT0 00FALSE00
2025-04-1740PUT0 00FALSE00
2025-04-1750.65PUT0 20FALSE00
2025-04-1760PUT0 00TRUE00
2025-04-177.50PUT0 091.33TRUE00
2025-04-1790PUT0 0131.95TRUE00
2025-04-17100PUT0 0135.74TRUE00
2026-01-1610CALL0 30TRUE00
2026-01-1620CALL0 20TRUE00
2026-01-1633CALL0 25783.56TRUE00
2026-01-1642CALL0 23659.94TRUE00
2026-01-1651.5CALL0 210148.67TRUE00
2026-01-1670.68CALL0 58846.48FALSE00
2026-01-16100.45CALL100 263450.08FALSE0.450
2026-01-16120.4CALL0 340FALSE00
2026-01-1610PUT0 410FALSE00
2026-01-1620PUT0 720FALSE00
2026-01-1630.3PUT0 460FALSE00
2026-01-1640.35PUT0 4600FALSE00
2026-01-1650.9PUT0 6930FALSE00
2026-01-1670PUT0 150TRUE00
2026-01-16100PUT0 087.51TRUE00
2026-01-16120PUT0 092.74TRUE00

Latest LOGC Trades:

Date Shares Price
Jun 13, 2022 7:47 PM EST200$0.4539
Jun 13, 2022 7:50 PM EST100$0.4499
Jun 13, 2022 7:50 PM EST200$0.4499
Jun 13, 2022 7:50 PM EST100$0.4499
Jun 13, 2022 7:50 PM EST100$0.4477

LogicBio Therapeutics, Inc (LOGC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520178928/0001193125-20-178928-index.htm
2019-11-21UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1664106/000000000019015732/0000000000-19-015732-index.htm
2020-05-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1664106/000000000020004765/0000000000-20-004765-index.htm
2020-06-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1664106/000000000020005085/0000000000-20-005085-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026987/0000899243-18-026987-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026988/0000899243-18-026988-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026992/0000899243-18-026992-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026993/0000899243-18-026993-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026994/0000899243-18-026994-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026998/0000899243-18-026998-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318026999/0000899243-18-026999-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027001/0000899243-18-027001-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027002/0000899243-18-027002-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027005/0000899243-18-027005-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027007/0000899243-18-027007-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027010/0000899243-18-027010-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027011/0000899243-18-027011-index.htm
2018-10-183Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027012/0000899243-18-027012-index.htm
2018-10-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027096/0000899243-18-027096-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027210/0000899243-18-027210-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027211/0000899243-18-027211-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027212/0000899243-18-027212-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027213/0000899243-18-027213-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027217/0000899243-18-027217-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027218/0000899243-18-027218-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027219/0000899243-18-027219-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027222/0000899243-18-027222-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027225/0000899243-18-027225-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027226/0000899243-18-027226-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027227/0000899243-18-027227-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027229/0000899243-18-027229-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027231/0000899243-18-027231-index.htm
2018-10-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027375/0000899243-18-027375-index.htm
2018-10-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027378/0000899243-18-027378-index.htm
2018-10-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027379/0000899243-18-027379-index.htm
2018-10-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027380/0000899243-18-027380-index.htm
2018-10-244/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027381/0000899243-18-027381-index.htm
2018-10-253/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027415/0000899243-18-027415-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027475/0000899243-18-027475-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027477/0000899243-18-027477-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027478/0000899243-18-027478-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027480/0000899243-18-027480-index.htm
2018-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027481/0000899243-18-027481-index.htm
2018-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924318027509/0000899243-18-027509-index.htm
2019-02-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924319004572/0000899243-19-004572-index.htm
2019-02-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924319004574/0000899243-19-004574-index.htm
2019-08-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924319022576/0000899243-19-022576-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000089924320027297/0000899243-20-027297-index.htm
2019-05-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1664106/000090266419002407/0000902664-19-002407-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1664106/000090266420000940/0000902664-20-000940-index.htm
2018-11-01SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1664106/000094787118000868/0000947871-18-000868-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000094787120000776/0000947871-20-000776-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000094787120000777/0000947871-20-000777-index.htm
2020-10-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1664106/000094787120000780/0000947871-20-000780-index.htm
2018-10-09S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1664106/000119312518295666/0001193125-18-295666-index.htm
2018-10-11S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1664106/000119312518297645/0001193125-18-297645-index.htm
2018-10-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1664106/000119312518300264/0001193125-18-300264-index.htm
2018-10-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1664106/000119312518300269/0001193125-18-300269-index.htm
2018-10-17S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1664106/000119312518301103/0001193125-18-301103-index.htm
2018-10-178-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1664106/000119312518301114/0001193125-18-301114-index.htm
2018-10-19POS EXPost-effective amendment adding exhibits to registration statement [Rule 462(d)]https://www.sec.gov/Archives/edgar/data/1664106/000119312518302176/0001193125-18-302176-index.htm
2018-10-22424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1664106/000119312518303289/0001193125-18-303289-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312518310599/0001193125-18-310599-index.htm
2018-11-02SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1664106/000119312518317070/0001193125-18-317070-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312518340421/0001193125-18-340421-index.htm
2018-12-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000119312518341169/0001193125-18-341169-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312518354565/0001193125-18-354565-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1664106/000119312519036007/0001193125-19-036007-index.htm
2019-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1664106/000119312519036039/0001193125-19-036039-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519057916/0001193125-19-057916-index.htm
2019-04-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519093656/0001193125-19-093656-index.htm
2019-04-0110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1664106/000119312519094593/0001193125-19-094593-index.htm
2019-04-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1664106/000119312519095708/0001193125-19-095708-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519105205/0001193125-19-105205-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519110925/0001193125-19-110925-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1664106/000119312519125202/0001193125-19-125202-index.htm
2019-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1664106/000119312519125235/0001193125-19-125235-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519146010/0001193125-19-146010-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000119312519146603/0001193125-19-146603-index.htm
2019-06-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519180202/0001193125-19-180202-index.htm
2019-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519184362/0001193125-19-184362-index.htm
2019-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519188256/0001193125-19-188256-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519219514/0001193125-19-219514-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000119312519219972/0001193125-19-219972-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519288366/0001193125-19-288366-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312519289315/0001193125-19-289315-index.htm
2019-11-15S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1664106/000119312519293465/0001193125-19-293465-index.htm
2019-11-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1664106/000119312519297651/0001193125-19-297651-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520005091/0001193125-20-005091-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520029995/0001193125-20-029995-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520074884/0001193125-20-074884-index.htm
2020-03-17S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1664106/000119312520075995/0001193125-20-075995-index.htm
2020-03-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520080815/0001193125-20-080815-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1664106/000119312520124363/0001193125-20-124363-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1664106/000119312520124383/0001193125-20-124383-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520139024/0001193125-20-139024-index.htm
2020-06-05DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1664106/000119312520161349/0001193125-20-161349-index.htm
2020-06-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1664106/000119312520162213/0001193125-20-162213-index.htm
2020-06-0510-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1664106/000119312520162226/0001193125-20-162226-index.htm
2020-06-0510-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000119312520162248/0001193125-20-162248-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520171447/0001193125-20-171447-index.htm
2020-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520178928/0001193125-20-178928-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520214074/0001193125-20-214074-index.htm
2020-09-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1664106/000119312520257792/0001193125-20-257792-index.htm
2020-09-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1664106/000119312520259681/0001193125-20-259681-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520259688/0001193125-20-259688-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1664106/000119312520262477/0001193125-20-262477-index.htm
2020-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520263197/0001193125-20-263197-index.htm
2020-11-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1664106/000119312520284838/0001193125-20-284838-index.htm
2019-11-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119057546/0001209191-19-057546-index.htm
2019-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119060530/0001209191-19-060530-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061660/0001209191-19-061660-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061662/0001209191-19-061662-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061663/0001209191-19-061663-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061664/0001209191-19-061664-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061665/0001209191-19-061665-index.htm
2019-12-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061666/0001209191-19-061666-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919119061671/0001209191-19-061671-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120009447/0001209191-20-009447-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120009448/0001209191-20-009448-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120009449/0001209191-20-009449-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120009450/0001209191-20-009450-index.htm
2020-03-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120020340/0001209191-20-020340-index.htm
2020-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120020355/0001209191-20-020355-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120024991/0001209191-20-024991-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120024992/0001209191-20-024992-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120024993/0001209191-20-024993-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038659/0001209191-20-038659-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038661/0001209191-20-038661-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038662/0001209191-20-038662-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038664/0001209191-20-038664-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038665/0001209191-20-038665-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038667/0001209191-20-038667-index.htm
2020-06-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1664106/000120919120038668/0001209191-20-038668-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1664106/000121390020003725/0001213900-20-003725-index.htm
2020-02-21SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1664106/000121390020004495/0001213900-20-004495-index.htm
2018-10-18CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1664106/000135445718000419/0001354457-18-000419-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000156459019042912/0001564590-19-042912-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1664106/000156459020011170/0001564590-20-011170-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000156459020024240/0001564590-20-024240-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1664106/000156459020038622/0001564590-20-038622-index.htm
2018-10-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1664106/999999999518002661/9999999995-18-002661-index.htm
2019-11-25EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1664106/999999999519002659/9999999995-19-002659-index.htm
2018-10-18CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1664106/999999999718008680/9999999997-18-008680-index.htm
2019-04-26CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1664106/999999999719003401/9999999997-19-003401-index.htm

LogicBio Therapeutics, Inc (LOGC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of LogicBio Therapeutics, Inc (LOGC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1369%
Institutional Ownership: 5300%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-10-23Tomer KarivDirectorBuy207,151.0010.002,071,510.001,574,564.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027480/0000899243-18-027480-index.htm
2018-10-23Tomer KarivDirectorBuy112,000.0010.001,120,000.001,686,564.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027480/0000899243-18-027480-index.htm
2018-10-23Sofia IoannidouDirectorBuy420,000.0010.004,200,000.001,787,413.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027478/0000899243-18-027478-index.htm
2018-10-23Tomer KarivDirectorBuy100,849.0010.001,008,490.001,787,413.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027480/0000899243-18-027480-index.htm
2020-09-28Bioscience plc Arix10% Share HolderSell273,584.007.542,061,865.822,381,436.00https://www.sec.gov/Archives/edgar/data/1664106/000089924320027297/0000899243-20-027297-index.htm
2020-09-25Bioscience plc Arix10% Share HolderSell174,219.007.081,232,947.862,655,020.00https://www.sec.gov/Archives/edgar/data/1664106/000089924320027297/0000899243-20-027297-index.htm
2020-09-24Bioscience plc Arix10% Share HolderSell38,514.007.63293,823.312,829,239.00https://www.sec.gov/Archives/edgar/data/1664106/000089924320027297/0000899243-20-027297-index.htm
2020-10-01Erez ChimovitsDirectorBuy296,296.006.001,777,776.00296,296.00https://www.sec.gov/Archives/edgar/data/1664106/000094787120000776/0000947871-20-000776-index.htm
2020-10-01ORBIMED ADVISORS LLCDirectorBuy296,296.006.001,777,776.00296,296.00https://www.sec.gov/Archives/edgar/data/1664106/000094787120000777/0000947871-20-000777-index.htm
2018-10-23Bioscience plc Arix10% Share HolderBuy700,000.0010.007,000,000.002,979,023.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027509/0000899243-18-027509-index.htm
2018-10-23Daniel P O'ConnellDirectorBuy700,000.0010.007,000,000.002,979,023.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027477/0000899243-18-027477-index.htm
2018-10-23Erez ChimovitsDirectorBuy490,000.0010.004,900,000.003,487,760.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027475/0000899243-18-027475-index.htm
2020-10-01Erez ChimovitsDirectorBuy545,974.006.003,275,844.003,524,997.00https://www.sec.gov/Archives/edgar/data/1664106/000094787120000776/0000947871-20-000776-index.htm
2020-10-01ORBIMED ADVISORS LLCDirectorBuy545,974.006.003,275,844.003,524,997.00https://www.sec.gov/Archives/edgar/data/1664106/000094787120000777/0000947871-20-000777-index.htm
2020-10-01Erez ChimovitsDirectorBuy639,212.006.003,835,272.004,126,972.00https://www.sec.gov/Archives/edgar/data/1664106/000094787120000776/0000947871-20-000776-index.htm
2020-10-01ORBIMED ADVISORS LLCDirectorBuy639,212.006.003,835,272.004,126,972.00https://www.sec.gov/Archives/edgar/data/1664106/000094787120000777/0000947871-20-000777-index.htm
2018-10-23ORBIMED ADVISORS LLCDirectorBuy490,000.0010.004,900,000.005,766,783.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027481/0000899243-18-027481-index.htm
2018-10-23ORBIMED ADVISORS LLCDirectorBuy700,000.0010.007,000,000.006,466,783.00https://www.sec.gov/Archives/edgar/data/1664106/000089924318027481/0000899243-18-027481-index.htm
2019-08-27Thomas WiltonChief Business OfficerBuy75,000.000.7354,750.0075,000.00https://www.sec.gov/Archives/edgar/data/1664106/000089924319022576/0000899243-19-022576-index.htm